Want to see TSE:LABS full AI Analyst Report?
LABS Stock Chart & Stats
C$0.08
<C$0.01(7.69%)
At close: 4:00 PM EST
C$0.08
<C$0.01(7.69%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.10
Previous CloseN/A
Volume690.59K
Average Volume (3M)466.64K
Market Cap
C$29.74M
Enterprise ValueC$19.89M
Total Cash (Recent Filing)C$9.87M
Total Debt (Recent Filing)C$18.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding424,864,260
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$38.98M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Cash BufferVery low leverage and a reported cash balance ($9.9M noted on the call) materially reduce refinancing and interest-rate risk. This durable financial flexibility supports ongoing operations, targeted M&A or regulatory filing costs and gives time to execute margin restoration without immediate capital raises.
High Gross Margin And Adjusted EBITDA ImprovementSustained ~37% gross margins and a return to positive adjusted EBITDA reflect improved product mix, pricing and cost control. These structural margin improvements increase the odds of converting sales into stable operating cash flow as volumes normalize and support reinvestment or further deleveraging over the medium term.
Regulatory Credentials And International TractionRare pharma-grade certifications and EU/HC/FDA credentials create durable competitive optionality for API and clinical supply contracts. Combined with growing regulated international orders, this supports more stable B2B demand and diversification away from single-market volatility over the next several quarters.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business still consumes cash despite margin gains. Over a 2–6 month horizon, continued cash burn could force reliance on the cash buffer or external financing, constraining strategic options and raising execution risk if revenue recovery stalls.
Top-line Weakness And Category ContractionA sizable YoY revenue decline and structural contraction in adult‑use/wellness limit the company's ability to leverage fixed cost reductions. Sustained top-line weakness undermines long-term operating leverage and makes it harder to convert improved gross margins into consistent positive net cash generation.
Reimbursement Cuts And Regulatory Timing RiskMaterial reimbursement cuts compress pricing in the Canadian medical channel and directly pressure margins; simultaneously, reliance on pending international authorizations creates timing risk. Together these structural policy and regulatory uncertainties can depress near-term revenue and prolong cash burn.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$29.74M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Aug 17, 2026 which is in 46 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on May 13, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.003 by C$0.003.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 424,864,260 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.003. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical entity, specializing in the creation and global commercialization of premium, pharmaceutical-grade cannabis oils, concentrates, and sophisticated derivative products. Its market reach extends across Canada, Australia, Germany, and other international territories. The company manages the full cycle from developing and processing to packaging and distributing a diverse array of cannabis extracts and advanced cannabinoid-based formulations. Furthermore, MediPharm Labs provides auxiliary services including GMP-certified flower procurement, specialized packaging, and comprehensive logistics. This enterprise was established in 2015 and has its corporate headquarters situated in Barrie, Canada.
LABS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear near-term challenges—most notably a ~16.7% YoY revenue decline, a widened net loss and industry reimbursement headwinds—with several material positives: return to positive adjusted EBITDA, a strong 37% gross margin, meaningful operating expense reductions (‑14% YoY, ‑28% sequential), $1.0M in expected annualized savings, $9.9M cash and limited debt, and continued international commercial traction (France, New Zealand, Brazil, Germany). Management emphasizes disciplined, margin-focused execution and long-term pharma optionality supported by rare regulatory credentials. Given the company's demonstrated ability to protect margins, improve profitability metrics and maintain liquidity while advancing international expansion, the tone is cautiously optimistic.View all TSE:LABS earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---